Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;517(1):207-213.
doi: 10.1134/S1607672924700911. Epub 2024 Jun 10.

Clinical Significance of Antibodies to DFS70 in Immunoinflammatory Rheumatic Diseases

T A Panafidina  1 , Zh G Verizhnikova  2 , A S Avdeeva  2 , T V Popkova  2 , E L Nasonov  2   3
Affiliations

Clinical Significance of Antibodies to DFS70 in Immunoinflammatory Rheumatic Diseases

T A Panafidina et al. Dokl Biochem Biophys. 2024 Aug.

Abstract

The relevance of the problem of immunoinflammatory rheumatic diseases (IIRD) for modern medicine is determined by their high prevalence in the population, the difficulty of early diagnosis, the rapid development of disability and poor life prognosis. Recent data on the significance of anti-DFS70 have opened up new possibilities for optimizing the step-by-step diagnosis of IIRD. The detection of these antibodies can help in the interpretation of a positive result for antinuclear antibodies (ANA) by indirect immunofluorescence assay on HEp-2 cells (IIFA-HEp-2) in the absence of autoantibodies specific for IIRD. Detection of anti-DFS70 in antinuclear factor (ANF) seropositive patients without clinical and/or serological markers characteristic of a certain disease from the IIRD group can be considered as a potential marker that excludes this group of diseases.

Keywords: anti-DFS70; antinuclear antibodies; immunoinflammatory rheumatic diseases; indirect immunofluorescence assay on HEp-2 cells.

PubMed Disclaimer

Similar articles

See all similar articles

References

REFERENCES

    1. Goldblatt, F. and O’neill, S.G., Clinical aspects of autoimmune rheumatic diseases, Lancet, 2013, vol. 382, no. 9894, pp. 797–808. https://doi.org/10.1016/s0140-6736(13)61499-3 - DOI - PubMed
    1. Davidson, A. and Diamond, B., Autoimmune diseases, New Engl. J. Med., 2001, vol. 345, no. 5, pp. 340–350. https://doi.org/10.1056/nejm200108023450506 - DOI - PubMed
    1. Hochberg, M.C., Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum., 1997, vol. 40, no. 9, pp. 1725–1725. https://doi.org/10.1002/art.1780400928 - DOI - PubMed
    1. Petri, M., Orbai, A.M., Alarcón, G.S., Gordon, C., and Merrill, J.T., Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus, Arthritis Rheum, 2012, vol. 64, no. 8, pp. 2677–2686. - DOI - PubMed - PMC
    1. Aringer, M., Costenbader, K.H., Daikh, D., Brinks, R., Mosca, M., et al., 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus, Ann. Rheum. Dis., 2019, vol. 78, no. 9, pp. 1151–1159. - DOI - PubMed

LinkOut - more resources